´ºÓêÖ±²¥app

´ºÓêÖ±²¥app

Development of a Blood Test for Earlier Diagnosis Than Conventional Amyloid PET Scans¡ªPotential Application for Screening Preclinical Alzheimer's Disease Before Symptoms Appear

Publish: June 12, 2025
Public Relations Office

June 12, 2025

´ºÓêÖ±²¥app School of Medicine

´ºÓêÖ±²¥app Hospital

A research team from the ´ºÓêÖ±²¥app Hospital Memory Center, led by Dr. Masato Kubota of Minna no Zaitaku Clinic Kokubunji (Assistant Professor at ´ºÓêÖ±²¥app School of Medicine (Clinical Training) at the time of the research) and Project Professor Daisuke Ito of the Department of Neurology, ´ºÓêÖ±²¥app School of Medicine, and the ´ºÓêÖ±²¥app Hospital Memory Center, has demonstrated that the amyloid-beta 42/40 ratio, measured using the simple blood test High Sensitivity Chemiluminescence Enzyme-immunoassay (HISCL?), can identify brain amyloid-beta (A¦Â) deposition¡ªa central pathology of Alzheimer's disease (AD)¡ªwith high accuracy and at an earlier stage than visual interpretation of amyloid PET scans. This plasma A¦Â42/40 is expected to be useful for screening preclinical AD.

These research findings were published in the online edition of the international medical journal Alzheimer's Research & Therapy on June 7, 2025.

Please see below for the full press release.

Press Release (PDF)